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Introductory Paragraph
Soft tissue sarcomas, which encompass approximately 10,700 diagnoses and 3800 deaths
per year in the US1, exhibit remarkable histologic diversity, with more than 50 recognized
subtypes2. However, knowledge of their genomic alterations is limited. We describe an
integrative analysis of DNA sequence, copy number, and mRNA expression in 207 samples
encompassing seven major subtypes. Frequently mutated genes included TP53 (17% of
pleomorphic liposarcomas), NF1 (10.5% of myxofibrosarcomas and 8% of pleomorphic
liposarcomas), and PIK3CA (18% of myxoid/round-cell liposarcomas). PIK3CA mutations
in myxoid/round-cell liposarcomas were associated with AKT activation and poor clinical
outcomes. In myxofibrosarcomas and pleomorphic liposarcomas, we found both point
mutations and genomic deletions affecting the tumor suppressor NF1. Finally, we found that
shRNA-based knockdown of several genes amplified in dedifferentiated liposarcoma,
including CDK4 and YEATS4, decreased cell proliferation. Our study yields a detailed map
of molecular alterations across diverse sarcoma subtypes and provides potential subtype-
specific targets for therapy.
Current knowledge of the key genomic aberrations in soft tissue sarcoma is limited to the
most recurrent alterations or translocations. Subtypes with simple, near-diploid karyotypes
bear few chromosomal rearrangements but have pathognomonic alterations: translocations
in myxoid/round-cell liposarcoma (MRC) [t(12;16)(q13;p11), t(12;22)(q13;q12)] and
synovial sarcomas (SS) [t(X;18)(p11;q11)]; activating mutations in KIT or PDGFRA in
gastrointestinal stromal tumors (GIST)3,4. The discovery of the latter mutations led to the
clinical deployment of imatinib for the treatment of GIST5, providing a model for genotype-
directed therapies in molecularly defined sarcoma subtypes. Conversely, sarcomas with
complex karyotypes, including dedifferentiated and pleomorphic liposarcoma,
leiomyosarcoma, and myxofibrosarcoma, have no known characteristic mutations or fusion
genes, although abnormalities are frequently observed in the Rb, p53, and specific growth-
factor signaling pathways6.
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Recent large-scale analyses7–10 have established a standard for cancer genome studies, but
soft tissue sarcomas have not yet been a focus of this type of effort. Given the urgent need
for new treatments for the ~4000 patients who die each year in the US of soft tissue
sarcoma1, we sought to identify novel genomic alterations that could serve as therapeutic
targets. Here, we describe complementary genome and functional genetic analyses of seven
subtypes of high-grade soft tissue sarcoma (Table 1 and Supplementary Table 1) to discover
subtype-specific events. Several of our findings, detailed below, could have nearly
immediate therapeutic implications.
To study the genomic alterations in sarcomas, we initially analyzed 47 tumor/normal DNA
pairs encompassing six soft tissue sarcoma subtypes by sequencing 722 protein-coding and
microRNA genes, followed by verifying discovered mutations with mass spectrometry-
based genotyping (see Methods, Supplementary Figure 1A, and Supplementary Table 2).
The results revealed 28 somatic non-synonymous coding point mutations and 9 somatic
insertions/deletions (indels) involving 21 genes in total (Table 2 and Supplementary Figure
1B). No mutations were detected in microRNAs genes. We extended the analysis to an
additional 160 tumors, where we genotyped each of the mutations found above and re-
sequenced exons of NF1 and ERBB4 in pleomorphic liposarcoma and myxofibrosarcoma,
PIK3CA and KIT in myxoid/round cell liposarcoma, and CDH1 in dedifferentiated
liposarcoma; this revealed nine additional mutations (Table 2 and Supplementary Table 3).
KIT was frequently mutated in GISTs and unexpectedly, in one myxoid/round cell
liposarcoma sample (Supplementary Note). The next most frequently mutated genes
observed within specific sarcoma subtypes were PIK3CA, in 18% of myxoid/round cell
liposarcomas, TP53 in 17% of pleomorphic liposarcomas (interestingly, the only subtype in
which mutations of this gene were found), and NF1 in 10.5% of myxofibrosarcomas and 8%
of pleomorphic liposarcomas (Table 2 and Figure 1). Additional genes, including protein
and lipid kinases, as well as known or candidate tumor suppressor genes, were found
mutated in just one sample for each sarcoma subtype (Table 2, Figure 1, and Supplementary
Note). Further studies will be needed to establish the functional impact of these mutations in
sarcoma.
Below, we focus on three major specific genomic findings with therapeutic implications:
point mutation and deletion of NF1 in a subset of soft tissue sarcomas, point mutation of
PIK3CA in myxoid/round cell liposarcoma, and the complex pattern of amplification of
chromosome 12q in dedifferentiated liposarcoma.
Integrated analysis of DNA copy number, expression, and mutation data uncovered diverse
alterations of the Neurofibromatosis type 1 gene (NF1) in several sarcoma subtypes. While
germline and somatic inactivation of NF1 is associated with malignant peripheral nerve
sheath tumors11 and GISTs in Neurofibromatosis type 1 patients12, no somatic NF1
alterations have been reported in other sarcomas. We detected six point mutations and
twelve genomic deletions encompassing the NF1 locus, occurring in both myxofibrosarcoma
and pleomorphic liposarcoma (Table 2 and Figure 1, 2A–B; copy number analysis discussed
further below). Two of the mutations, R304* and Q369*, were previously reported as
germline mutations in patients with Neurofibromatosis type 113,14, while the other four
mutations (three missense and one nonsense) have not been previously reported. In some
tumors, biallelic inactivation was evident, with heterozygous point mutations accompanied
by deletion of the wild-type allele and correspondingly reduced gene expression compared
to normal adipose tissue15 in most cases (Figure 2B). Together, these data indicate a diverse
pattern of NF1 aberrations in myxofibrosarcomas and pleomorphic liposarcomas. These
results complement recent reports of NF1 alterations in lung cancers and glioblastomas7,8.
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PIK3CA, encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), had one of
the highest somatic mutation frequencies among the genes in this analysis (Table 2).
Nucleotide substitutions in PIK3CA were initially detected in 4 of 21 myxoid/round-cell
liposarcomas (MRCs). We measured the frequency of point mutations in PIK3CA in this
subtype by genotyping an independent cohort of 50 MRCs16 for 13 common sites of
PIK3CA mutation, including those discovered in our initial sequencing; mutations were
detected in 9 additional patients (in total, 13 of 71). The mutations were clustered in two
domains, the helical domain (E542K and E545K) and the kinase domain (H1047L and
H1047R) (Table 2); both these domains are also mutated in epithelial tumors17.
MRC patients whose tumors harbored mutations in PIK3CA had a shorter duration of
disease–specific survival than did those with wildtype PIK3CA (p=0.036, log-rank test).
Similar to observations in breast cancers18, patients with helical-domain PIK3CA mutations
had worse outcomes than those with kinase-domain mutations (Figure 3A). However, this
difference was not statistically significant given the small number of cases in our study.
As both helical- and kinase-domain PIK3CA mutants are believed to activate Akt, although
through different mechanisms19–21, we assessed Akt activation in MRC tumors harboring
wildtype and mutated PIK3CA. Of note, only E545K helical-domain mutations were
associated with increased Akt phosphorylation relative to wildtype, both at serine-473 and
threonine-308 (TORC2 and PDK1 phosphorylation sites, respectively), and with increased
phosphorylation of Akt substrates PRAS40 and S6 kinase (Figure 3B). Surprisingly, tumors
with H1047R kinase-domain mutations did not have similar increases in Akt
phosphorylation or activation (Figure 3B). However, H1047R-mutant tumors exhibited
variably higher levels of PTEN, a negative regulator of PI3K activity, which may partly
explain lower Akt activity. In addition, we detected a single MRC tumor with homozygous
PTEN deletion and high Akt phosphorylation levels (data not shown). Further studies are
needed to determine the relationship between activated PI3K signaling (resulting from
PIK3CA mutations) and the pathognomonic t(12;16)(q13;p11) translocation in this subtype.
In addition to sequencing, we characterized the spectrum of genomic aberrations in soft
tissue sarcoma with 250K single nucleotide polymorphism (SNP) arrays for somatic copy
number alterations (SCNAs: n=207; Figure 1 and Supplementary Figure 2A) and loss-of-
heterozygosity (LOH) (n=200; Supplementary Figure 2B) and with oligonucleotide gene
expression arrays (n=149) (see Methods). The patterns of statistically significant
SCNAs22,23 (Figure 1) revealed substantial differences between subtypes with simple and
complex karyotypes (Figure 1). Myxoid/round-cell liposarcoma, synovial sarcoma, and
GIST had relatively normal karyotypes compared to dedifferentiated and pleomorphic
liposarcoma, leiomyosarcoma, and myxofibrosarcoma. In addition, only the four complex
subtypes harbored significant copy-neutral LOH (Supplementary Figure 2B and
Supplementary Table 4). These types exhibit varied levels of complexity: both
dedifferentiated liposarcoma and leiomyosarcoma are less complex than pleomorphic
liposarcoma and myxofibrosarcoma (Figure 1). The latter two subtypes were strikingly
similar (Figure 1 and Supplementary Figure 2A), indicating they might appropriately be
considered a single entity in a molecular classification, as previously suggested24.
Our copy number profiling revealed both focal and broad regions of recurrent amplification
(Supplementary Table 5). The alteration with the highest prevalence in any subtype was
chromosome 12q amplification in dedifferentiated liposarcoma (~90%; Figure 1 and Figure
4A). As amplification is a common mechanism of oncogenic activation, we designed an
RNA interference (RNAi) screen to help identify genes in amplified regions that are
necessary for cancer cell proliferation in this subtype. We performed knockdown with short
hairpin RNAs (shRNA) on 385 genes (Supplementary Table 2) in three dedifferentiated
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liposarcoma cell lines (LPS141, DDLS8817, and FU-DDLS-1) with copy number profiles
similar to those observed in primary tumors of this subtype. A total of 2,007 shRNA
lentiviruses, a median of five per gene, were tested for their effects on cell proliferation after
5 days (see Methods).
Using a statistical method, RSA (see Methods, Supplementary Note, and ref. 25), we
identified 99 genes whose knockdown significantly decreased cell growth in at least one cell
line (nominal p<0.05; Supplementary Table 6). For 91 of the 99 genes, two or more
independent shRNAs had anti-proliferative activity, reducing the likelihood that our results
are due to off-target effects. To determine whether the effect of gene knockdown on cell
proliferation was specific for dedifferentiated liposarcoma, we compared our results to a
pooled shRNA screen of ~9500 genes in 12 cancer cell lines of different types26 which
included 58 of the 99 genes whose knock-down reduced proliferation. Only one of the 58
genes, PSMB4, was identified as a common essential gene, for which depletion reduced cell
proliferation in ≥8 of 12 cancer cell lines in the prior study26.
27 of the 99 genes whose knockdown reduced proliferation were amplified in at least one of
the three dedifferentiated liposarcoma cell lines used in our study (Supplementary Figure 3).
Among these 27 genes, the most strongly overexpressed in dedifferentiated liposarcoma
compared to normal fat15 was CDK4, a cell-cycle regulator and a known oncogene27. We
confirmed that sustained knockdown of CDK4 (>10 days) inhibited proliferation when we
assayed two of the three cell lines we screened (see Methods, Figure 4B). Furthermore,
pharmacological inhibition of CDK4 in dedifferentiated liposarcoma cells with PD0332991,
a selective CDK4/CDK6 inhibitor currently in clinical trials28, induced G1 arrest in the same
two cell lines (Figure 4C).
For MDM2, another oncogene found in focal 12q amplifications, knockdown did not
significantly impair proliferation in our arrayed screen in any of the three cell lines tested.
Nevertheless, proliferation was impaired by subsequent knockdown lasting more than a
week when we assayed two of those three cell lines (Figure 4D). Interestingly, another gene
whose knockdown reduced proliferation of cells in which it was amplified was YEATS4
(GAS41), encoding a putative transcription factor that represses the p53 tumor suppressor
network during normal cell proliferation29. YEATS4, frequently co-amplified with MDM2
(Figure 4A), was transcriptionally upregulated both in tumors relative to normal adipose
tissue and in tumors with amplification compared to those copy-neutral for the locus
(Supplementary Figure 3). Repeat shRNA experiments confirmed the effect of YEATS4
knockdown seen in the arrayed screen (Figure 4E), consistent with the hypothesis that
YEATS4 and MDM2 amplification may cooperatively repress the p53 network in
dedifferentiated liposarcoma, as recently suggested30. This finding may have consequences
for Nutlin-based antagonism of the p53-MDM2 interaction15,31 in dedifferentiated
liposarcomas. Our findings lend additional support for YEATS4 serving as a likely key
amplified gene in cancer, as recently suggested through a weight-of-evidence classification
scheme proposed for identifying such amplified cancer genes32.
This dataset provides the most comprehensive database of sarcoma genome alterations to
date, revealing genes and signaling pathways not previously associated with this group of
diseases. The study results are available as a community resource that might further the
biological understanding of sarcomas and, eventually, shed light on additional strategies to
improve patient care. Some of our findings already have potential therapeutic implications.
For instance, the PIK3CA mutations found in MRC constitute the first report of such
mutations in a mesenchymal cancer. These mutations identify a subset of tumors that might
respond to treatment with PI3K inhibitors currently in clinical trials33. Our results also
provide further rationale for use of CDK4 inhibitors in dedifferentiated liposarcoma and
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suggest the use of mTOR inhibitors in NF1-deficient sarcomas, since loss of NF1 function
appears to cause mTOR pathway activation34. Finally, these data lend support for the
clinical evaluation of agents targeting the p53/MDM2 interaction in dedifferentiated
liposarcoma.
This work argues for the therapeutic importance of genomic alterations in sarcoma and
encourages us to pursue next-generation sequencing strategies that will continue to define
the landscape of genomic aberrations in these deadly diseases.
Methods
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturegenetics/.
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Figure 1. Nucleotide and copy number alterations in soft-tissue sarcoma subtypes
The statistical significance of genomic aberrations for each subtype is shown. RAE q-values
[left axis; for visualization, q-values ≤ 0.05 are considered significant, corresponding false
discovery rate (FDR) ≤ 5%] and scores (right axis) for gains and amplifications (red) and
losses and deletions (blue) are plotted across the genome (chromosomes indicated at
bottom). Genes harboring somatic nucleotide alterations in this study are indicated in each
subtype in which they were discovered (Table 2).
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Figure 2. NF1 alterations in karyotypically complex sarcomas
A. Somatic mutations in the NF1 protein in myxofibrosarcoma and pleomorphic
liposarcoma (black triangles) and the position of the RasGAP and Cral domains (dark and
light green respectively) are juxtaposed to known mutations in malignant peripheral nerve
sheath tumors (MPNSTs; open triangles). B. Transcript expression according to copy
number and sequence status in myxofibrosarcoma and pleomorphic liposarcoma compared
to normal adipose tissue samples (black/red and green respectively, log2 expression from
Affymetrix array profiling data; p-value=1.94×10−5, ANOVA; mutated tumors are
indicated). One of the two R304* mutant tumors lacked expression data.
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Figure 3. Different effect of helical and kinase domain PIK3CA mutations on PI3K pathway
activation and survival in myxoid/round-cell liposarcoma
A. Survival for patients with tumors that harbor helical-domain mutations (red) versus
kinase-domain mutations (grey), and wildtype PIK3CA (blue). The analysis includes the 65
patients for whom outcome information was available. Patients with mutations in either the
helical or the kinase domain had a shorter disease–specific survival compared to those with
wildtype PIK3CA (p-value = 0.0363, log-rank test). The difference in disease-specific
survival between patients with helical-domain mutant tumors and those with wildtype
PIK3CA tumors was significant (p-value=0.013, log-rank test). B. Western blots of myxoid/
round-cell liposarcoma tumor lysates comparing the phosphorylation levels of Akt,
PRAS40, and S6 kinase, as well as their protein levels, in patients with wild-type PIK3CA or
with mutations in PIK3CA helical or kinase domains.
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Figure 4. Genes whose knockdown is anti-proliferative in dedifferentiated liposarcoma and the
consequences of CDK4, MDM2 and YEATS4 knockdown in dedifferentiated liposarcoma
(A) Integrated profile of statistically significant genomic gains/amplifications as assessed by
both RAE and GISTIC (combined as described in Methods; FDR, false-discovery rate) is
followed by a heatmap of copy number segmentation on 12q13.2-q32.1 in 50 patient
samples of dedifferentiated liposarcomas (red is amplification, blue is deletion, each row
indicates one tumor sample). Below is the position of genes from our screen encoded by this
region of 12q whose knockdown is anti-proliferative in dedifferentiated liposarcoma. Bold
gene symbols indicate those whose amplification produced over-expression of its transcript
or those over-expressed in tumor relative to normal adipose tissue. Genes in green are
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highlighted in panels B–C and E. Alternative genomic regions encoding genes not on 12q
whose knockdown is anti-proliferative are also included. (B) Effect of three validated
shRNAs targeting CDK4 on the proliferation of two cell lines, LPS141 and DDLS8817, at
various time points (x-axis) with negative controls (pLKO empty vector and GFP473).
Below are western blots showing the effect of shRNAs on levels of CDK4 protein (as
indicated). (C) G1 arrest induced in LPS141 and DDLS8817 cell lines by treatment with the
CDK4/CDK6 inhibitor PD0332991. MDA-MB-435 (Rb-positive) and H2009 (Rb-negative)
were included as sensitive and insensitive controls. Error bars are s.d. of replicate
measurements. (D–E) As in panel (B), effect on proliferation of three shRNAs targeting
MDM2 (panel D) and YEATS4 (panel E) (negative controls: pLKO empty vector and
scrambled shRNA) where each targeting shRNA resulted in reduced protein levels (at
bottom). Error bars are propagated error from the ratio of mean and s.d. of measurements/
replicates to time 0.
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Table 1
Summary of clinical and pathologic information for 207 soft-tissue sarcoma patients
Characteristic Value
No. of patients 207
Age [mean±SD (range)] 56±16 (7–84)
Gender (%) †
  Female 102 (50.2)
  Male 101 (49.8)
Tumor size §
  0–5 cm 35 (17.4)
  5–10 cm 65 (32.3)
  10–15 cm 43 (21.4)
  >15 cm 58 (28.9)
Primary site (%) †
  Retro-intrabdominal 60 (29.6)
  Visceral
    Gastrointestinal 23 (11.3)
    Genitourinary 4 (2)
    Gynecological 1 (0.5)
  Thoracic 12 (5.9)
  Extremity 93 (45.8)
  Trunk 8 (3.9)
  Head and Neck 2 (1)
Stage at time of sample procurment ‡
  Primary 139 (68.8)
  Local recurrence 29 (14.4)
  Distant recurrence 34 (16.8)
Histology
  Dedifferentiated liposarcoma 50 (24.2)
  Myxoid/round cell liposarcoma 21 (10.1)
  Pleomorphic liposarcoma 24 (11.6)
  Leiomyosarcoma 27 (13)
  Gastrointestinal stromal tumor
    Epithelioid 4 (1.9)
    Spindle 11 (5.3)
    Mixed or unspecified 7 (3.4)
  Myxofibrosarcoma
    Myxofibrosarcoma 35 (16.9)
    Pleomorphic MFH 3 (1.5)
  Synovial sarcoma ‖
    Monophasic 19 (9.2)
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Characteristic Value
    Biphasic 4 (1.9)
Median follow-up (months) 35.65
Time to distant recurrence (months) 15.7
Co-morbidities 57 (27.5)
‖
One synovial sarcoma not specified
Data available for §201, †203, and ‡202 patients respectively
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